secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2026-10-19T13:15:23+00:00
Accession:  0001437749-26-032887
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

BioCardia says FDA accepted Helix catheter De Novo pre-submission; review meeting expected this quarter
--------------------------------------------------------------------------------

- FDA accepted BioCardia's revised De Novo pre-submission package for marketing clearance of the Helix transendocardial delivery catheter, per the Oct. 19, 2026 release.
- In May 2026 FDA agreed two pathways exist for Helix clearance and raised no concerns on the product's safety data, performance, or compatibility with general classes of agents.
- FDA confirmed the meeting minutes in August 2026; BioCardia revised and resubmitted the package in September 2026 incorporating CDRH advice.
- Substantive review with written FDA feedback, followed by a meeting to discuss De Novo approval, is expected this quarter.
- Helix data covers 15 clinical trials and nearly 500 patients; clearance could expand partnering with cell, gene and protein therapeutic developers needing heart delivery.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774926032887/0001437749-26-032887-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774926032887/bcda20261018_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-032887

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer